Needham Maintains Buy on Axonics, Raises Price Target to $78

Needham analyst Mike Matson maintains Axonics (NASDAQ:AXNX) with a Buy and raises the price target from $72 to $78.

byBenzinga Newsdesk

June 28, 2021

1 minute read

Needham analyst Mike Matson maintains Axonics (NASDAQ:AXNX) with a Buy and raises the price target from $72 to $78.

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

By Vandana Singh

Today, 3:41 AM

Arbutus Biopharma Corporation (NASDAQ:ABUS) and Vaccitech plc (NASDAQ:VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving…

ABUS

FDA
News

‘Covaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government’ -NDTV Report. BZ NOTE: Ocugen Is A Partner On Covaxin

By Benzinga Newsdesk

Today, 3:41 AM

https://www.ndtv.com/india-news/covaxin-granted-emergency-use-listing-in-13-nations-as-on-jan-31-according-to-who-govt-2749724

OCGN

Harvest Health Reports 84% YoY Higher Revenue Of $102.5M; Cantor Fitzgerald Sets $3.85 Price Target Based On Trulieve Acquisition Price

By Nina Zdinjak

Today, 3:41 AM

Harvest Health & Recreation Inc. (CSE: HARV) (OTCQX: HRVSF) posted its second-quarter revenue of $102.5 million, up by 84% from $55.7 million in the same period of 2020.

CSE:HARV

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

By Vandana Singh

Today, 3:41 AM

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine.

ADPT

Needham Maintains Buy on Axonics, Raises Price Target to $78

Related Posts

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

‘Covaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government’ -NDTV Report. BZ NOTE: Ocugen Is A Partner On Covaxin

Harvest Health Reports 84% YoY Higher Revenue Of $102.5M; Cantor Fitzgerald Sets $3.85 Price Target Based On Trulieve Acquisition Price

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO